In a news release last week, the Food and Drug Administration (FDA) issued an announcement that it will be “significantly” reducing the use of the controversial diabetes medication Avandia.  The drug is only to be given to patients with type 2 diabetes who cannot otherwise control the disease with other medications.

However, while the drug is still available in the United States, the European Union’s European Medicines Agency announced in a press release that they are recommending the suspension of the marketing of Avandia, and it will no longer be available in Europe within the next few months. The press release goes on to advise that patients currently taking Avandia should visit their physicians to discuss alternative treatments because doctors will no longer be allowed to prescribe the drug.

Avandia (rosiglitazone) is a drug, developed by GlaxoSmithKline (GSK), used for the treatment of type 2 diabetes.  It was approved by the Food and Drug Administration (FDA) in 1999. However, since the approval of the drug the FDA has continued monitoring several heart related adverse effects that were of concern during clinical trials.  In 2006 & 2007, the FDA requested that the labeling for the drug be changed as new data showed the potential risks of the drug.

Since 2006 Avandia users have reported numerous side effects, some of which caused severe medical problems:

  • Headaches and back pain
  • Anemia
  • Swelling or water weight gain (edema)
  • Bone fractures in upper arms, hands, and feet
  • Vision problems, including partial blindness
  • Upper respiratory infections, similar to colds
  • Heart disease, heart attack
  • Increased risk of stroke
  • Liver failure
  • Death

If you or a loved one have experienced physical or mental problems due to Avandia use, you may be eligible for inclusion in our class-action lawsuit against the manufacturers.
Contact us via e-mail, or call toll free 877-664-9365.

www.Avandia-Lawsuit-Lawyer.com

 
 

Theme by HermesThemes

Copyright © 2013 Law Offices of Richard J. Serpe, PC. All Rights Reserved